Pharmacological Characterization ofN,N-Dimethyl-2-(2-amino-4-methylphenyl thio)benzylamine as a Ligand of the Serotonin Transporter with High Affinity and Selectivity

Serotonin transporter has a key-role in regulation of serotoninergic function, and is involved in numerous neurodegenerative and psychiatric disorders. To obtain an efficient radioactive ligand allowing the study of this transporter in vitro and in vivo, we synthesized a new diphenyl sulfide derivative,N,N-dimethyl-2-(2-amino-4-methylphenylthio)benzylamine or MADAM. We present here extensive pharmacological characterization of this compound. [3H]MADAM bound to serotonin transporters with a very high affinity in vitro on rat cortical membranes, at least 2 times better than the most commonly used radioactive probes (K d, 60 pM; B max, 543 fmol/mg of protein). Competition studies showed few inhibitory effect of nisoxetine (K i = 270 nM), no inhibitory effect of desipramine or 1-[2-(diphenylmethoxy) ethyl]-4-(3-phenylpropyl)piperazine (GBR 12935) (K i >1000 nM), and strong effect of paroxetine (K i = 0.32 nM) and citalopram (K i = 1.57 nM). Therefore, MADAM has around 1000-fold better selectivity for the serotonin transporter than for other transporters. Autoradiographic studies both on rat and postmortem human brain slices demonstrated that the distribution of [3H]MADAM parallels the localization of serotonin transporters and is prevented by known inhibitors of them. The high affinity and selectivity of [3H]MADAM for the serotonin transporter show that it is very valuable for studies using in vitro approaches. The high selectivity and low nonspecific binding of [3H]MADAM on the postmortem human brain, together with preliminary in vivo results with [11C]MADAM, is a new argument for future use of this ligand in in vivo studies of the distribution, pharmacology, and pathophysiology of the serotonin transporter in the human brain with positron emission tomography.

[1]  J. Seibyl,et al.  Age-related decline in central serotonin transporter availability with [123I]β-CIT SPECT , 2000, Neurobiology of Aging.

[2]  J Tauscher,et al.  Imaging serotonin and dopamine transporters with 123I-beta-CIT SPECT: binding kinetics and effects of normal aging. , 2000, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[3]  P. Acton,et al.  2-((2-((dimethylamino)methyl)phenyl)thio)-5-iodophenylamine (ADAM): an improved serotonin transporter ligand. , 2000, Nuclear medicine and biology.

[4]  R. Summers,et al.  Antidepressant binding sites in brain: autoradiographic comparison of [3H]paroxetine and [3H]imipramine localization and relationship to serotonin transporter. , 1990, The Journal of pharmacology and experimental therapeutics.

[5]  Y. Cheng,et al.  Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. , 1973, Biochemical pharmacology.

[6]  A. Pawlyk,et al.  Altered serotonin transporter sites in Alzheimer's disease raphe and hippocampus. , 1995 .

[7]  D. Scherman,et al.  Quantitative autoradiography of the rat brain vesicular monoamine transporter using the binding of [3H]dihydrotetrabenazine and 7-amino-8-[125I]iodoketanserin , 1989, Neuroscience.

[8]  D Guilloteau,et al.  Synthesis and ligand binding of nortropane derivatives: N-substituted 2beta-carbomethoxy-3beta-(4'-iodophenyl)nortropane and N-(3-iodoprop-(2E)-enyl)-2beta-carbomethoxy-3beta-(3',4'-disubstituted phenyl)nortropane. New high-affinity and selective compounds for the dopamine transporter. , 1997, Journal of medicinal chemistry.

[9]  J. Kornhuber,et al.  SPECT imaging of dopamine and serotonin transporters with [123I]β-CIT. Binding kinetics in the human brain , 2005, Journal of Neural Transmission / General Section JNT.

[10]  P. Hrdina,et al.  Chronic fluoxetine treatment upregulates 5‐HT uptake sites and 5‐HT2 receptors in rat brain: An autoradiographic study , 1993, Synapse.

[11]  S. Snyder,et al.  Selective labeling of serotonin uptake sites in rat brain by [3H]citalopram contrasted to labeling of multiple sites by [3H]imipramine. , 1987, The Journal of pharmacology and experimental therapeutics.

[12]  P. Acton,et al.  A new single-photon emission computed tomography imaging agent for serotonin transporters: [123I]IDAM, 5-iodo-2-((2-((dimethylamino)methyl)phenyl)thio)benzyl alcohol. , 1999 .

[13]  C. Halldin,et al.  Substituted diphenyl sulfides as selective serotonin transporter ligands: synthesis and in vitro evaluation. , 2002, Journal of medicinal chemistry.

[14]  Y. Claustre,et al.  Characterization of [3H]paroxetine binding to rat cortical membranes. , 1985, European journal of pharmacology.

[15]  M. Eldefrawi,et al.  High affinity stereospecific binding of [3H] cocaine in striatum and its relationship to the dopamine transporter. , 1987, Membrane biochemistry.

[16]  B. Cooper,et al.  Pharmacological Properties of 403U76, a New Chemical Class of 5‐Hydroxytryptamine‐ and Noradrenaline‐reuptake Inhibitor , 1995, The Journal of pharmacy and pharmacology.

[17]  Denis Guilloteau,et al.  Carbon-11 labelling of MADAM in two different positions: a highly selective PET radioligand for the serotonin transporter , 2001 .

[18]  F I Carroll,et al.  High‐affinity binding of [125I]RTI‐55 to dopamine and serotonin transporters in rat brain , 1992, Synapse.

[19]  M. Kaufman,et al.  Cocaine accumulates in dopamine‐rich regions of primate brain after I.V. Administration: Comparison with mazindol distribution , 1994, Synapse.

[20]  G. Sedvall,et al.  Whole hemisphere autoradiography of the postmortem human brain. , 1998, Nuclear medicine and biology.

[21]  J. Sandell,et al.  Precursor synthesis and radiolabelling of [11C]ADAM: a potential radioligand for the serotonin transporter exploration by PET , 2001 .

[22]  P. Acton,et al.  Quantification of serotonin transporters in nonhuman primates using [(123)I]ADAM and SPECT. , 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[23]  G. Paxinos,et al.  The Rat Brain in Stereotaxic Coordinates , 1983 .

[24]  T. Reader,et al.  Effects of chronic antidepressant treatments on 5-HT and NA transporters in rat brain: an autoradiographic study , 2001, Neurochemistry International.

[25]  D. Guilloteau,et al.  Synthesis and Ligand Binding of Nortropane Derivatives: N‐Substituted 2β‐Carbomethoxy‐3β‐(4′‐iodophenyl)nortropane and N‐(3‐ Iodoprop‐(2E)‐enyl)‐2β‐carbomethoxy‐3β‐(3′,4′‐disubstituted phenyl)nortropane. New High‐Affinity and Selective Compounds for the Dopamine Transporter. , 1997 .

[26]  H. Schoemaker,et al.  5‐Methoxytryptoline, a Competitive Endocoid Acting at [3H]Imipramine Recognition Sites in Human Platelets , 1985, Journal of neurochemistry.

[27]  Y. Moriyama,et al.  Vesicular Monoamine Transporter 1 Is Responsible for Storage of 5‐Hydroxytryptamine in Rat Pinealocytes , 1999, Journal of neurochemistry.

[28]  M Laruelle,et al.  Methyl 3 beta-(4-[125I]iodophenyl)tropane-2 beta-carboxylate in vitro binding to dopamine and serotonin transporters under "physiological" conditions. , 1994, Journal of neurochemistry.

[29]  D. Vergé,et al.  Serotoninergic neurons and serotonin receptors: gains from cytochemical approaches , 2000, Journal of Chemical Neuroanatomy.

[30]  M Slifstein,et al.  In vivo quantification of brain serotonin transporters in humans using [11C]McN 5652. , 2000, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[31]  S. Houle,et al.  Novel Radiotracers for Imaging the Serotonin Transporter by Positron Emission Tomography: Synthesis, Radiosynthesis, and in Vitro and ex Vivo Evaluation of (11)C-Labeled 2-(Phenylthio)araalkylamines. , 2000, Journal of medicinal chemistry.

[32]  Linda Carpenter,et al.  Reduced brain serotonin transporter availability in major depression as measured by [123I]-2β-carbomethoxy-3β-(4-iodophenyl)tropane and single photon emission computed tomography , 1998, Biological Psychiatry.

[33]  J. Karhu,et al.  Iodine-123 labeled nor-β-CIT as a potential tracer for serotonin transporter imaging in the human brain with single-photon emission tomography , 1997, European Journal of Nuclear Medicine.

[34]  E. D. De Souza,et al.  Autoradiographic localization of 3H‐paroxetine‐labeled serotonin uptake sites in rat brain , 1987, Synapse.

[35]  R. Blakely,et al.  Antidepressant- and cocaine-sensitive human serotonin transporter: molecular cloning, expression, and chromosomal localization. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[36]  M. M. Bradford.  A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. , 1976, Analytical biochemistry.

[37]  J. Seibyl,et al.  Age-related decline in central serotonin transporter availability with [(123)I]beta-CIT SPECT. , 2000, Neurobiology of aging.

[38]  S. Gershon,et al.  Tritiated imipramine binding sites are decreased in the frontal cortex of suicides. , 1982, Science.

[39]  J. Palacios,et al.  Serotoninergic terminal transporters are differentially affected in Parkinson's disease and progressive supranuclear palsy: An autoradiographic study with [3H]citalopram , 1993, Neuroscience.

[40]  I. Ferrier,et al.  Studies on the serotonin uptake binding site in major depressive disorder and control post-mortem brain: Neurochemical and clinical correlates , 1991, Psychiatry Research.

[41]  R. Blakely,et al.  Cloning and expression of a functional serotonin transporter from rat brain , 1991, Nature.

[42]  Alan A. Wilson,et al.  Positron Emission Tomography Quantification of [11C]-DASB Binding to the Human Serotonin Transporter: Modeling Strategies , 2001, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[43]  P. Acton,et al.  Selective in vitro and in vivo binding of [125I]ADAM to serotonin transporters in rat brain , 2000, Synapse.

[44]  Y. Hurd,et al.  Human brain imaging post-mortem - whole hemisphere technologies , 2001 .